Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 21;26(7):195.
doi: 10.1208/s12249-025-03188-3.

Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications

Atif Husain  1 , Poonam Kushwaha  2 , Archita Kapoor  1 , Priyanka Singh  1
Affiliations
Review

Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications

Atif Husain et al. AAPS PharmSciTech. .

Abstract

Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes and immune dysregulation, leading to erythematous, scaly plaques. Conventional treatments, including corticosteroids, immunosuppressants, and biologics, often present challenges such as systemic side effects, poor skin penetration, and reduced patient compliance. Lipid nanocarriers (LNCs) have emerged as promising drug delivery systems for psoriasis management, offering enhanced drug stability, targeted delivery, improved skin penetration, and controlled drug release. This review explores the advancements in LNC-based formulations, including solid lipid nanoparticles, nanostructured lipid carriers, liposomes, and ethosomes, highlighting their advantages over traditional therapies. The physicochemical properties, mechanisms of skin penetration, and therapeutic efficacy of LNCs in psoriasis treatment are discussed, along with preclinical and clinical findings. The integration of lipid nanocarriers into psoriasis treatment regimens holds significant promise for improving patient outcomes by providing more effective and safer therapeutic alternatives.

Keywords: Drug delivery; Lipid nanocarriers; Nanostructured lipid carriers; Psoriasis; Psoriasis treatment; Skin penetration.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human Ethics and Consent to Participate: Not applicable. Conflicts of interest: The authors declare no financial or other conflicts of interest.

Similar articles

See all similar articles

References

    1. World Health Organization. Global report on psoriasis. World Health Organization, 2016.
    1. Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1260–344.
    1. Sieminska I, Pieniawska M, Grzywa TM. The Immunology of Psoriasis—Current Concepts in Pathogenesis. Clin Rev Allergy Immunol. 2024;20:1–28.
    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60. - PubMed
    1. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5):490–5. - PubMed

LinkOut - more resources